SC-ADTRAN-HOLDINGS,-INC.
15.5.2024 14:01:32 CEST | Business Wire | Press release
Adtran today announced that TruVista is harnessing its ALM fiber monitoring solution to ensure the reliability of its high-speed broadband services. Adtran’s ALM gives TruVista’s maintenance teams comprehensive and immediate insight into their optical infrastructure, including third-party links. By continuously probing the fiber network for breaks, bends, damage and more, the technology empowers field forces to take swift, targeted action to resolve any issues. This proactive approach enables TruVista to deliver ultra-reliable high-speed connectivity even more efficiently, ensuring its subscribers benefit from robust, sustainable and secure services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515244858/en/
Adtran’s ALM is providing TruVista with real-time data on its fiber network, enabling rapid response to any issues. (Photo: Business Wire)
“At TruVista, enhancing the subscriber experience is our top priority. That’s why we chose to elevate our services by leveraging Adtran’s comprehensive fiber assurance platform,” said Sam Fitzgerald, VP of technology at TruVista. “We have a lot of fiber spread across a huge expanse of land. Given this scale, we need the best possible protection against unpredictable events like storm damage or accidental cuts. Real-time, in-service monitoring of our network is critical to promptly identify and address any anomalies. ALM enables us to detect the slightest issues as soon as they occur, giving our network an essential layer of protection. It ensures that our subscribers consistently receive the best possible broadband experience.”
TruVista is utilizing Adtran’s ALM technology to enhance service delivery for its residential and business subscribers across South Carolina and Georgia. Engineered for power efficiency, ALM protects the company’s investment and ensures consistent service quality. It works seamlessly with any optical transmission technology, enabling swift fiber fault detection irrespective of the network equipment used. The system monitors the network in real-time and provides precise alerts for faults, irregularities or security breaches. With access to detailed performance data, TruVista is reducing the need for truck rolls and cutting operational costs, helping to streamline network management and bolstering service reliability.
“Over the last ten years, we’ve helped TruVista build a network spanning two states, enabling tens of thousands of subscribers to play, stream, learn and work from home. Now, by deploying our ALM, they join a growing list of forward-thinking service providers who are making their networks more robust, reliable and secure. With ALM surveilling TruVista’s fiber 24/7, the efficiency of their high-quality broadband services just got a major boost,” commented John Scherzinger, GM of Americas sales at Adtran. “What sets our ALM apart is its ease of use and open management interfaces. Simply drop it into your network and it instantly starts monitoring the physical integrity of any fiber link. It’s completely service-agnostic. This simplicity and versatility are what make it so appealing to service providers.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515244858/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom